Aclaris Therapeutics Reports Q2 2026 Financial Results

What Happened
Aclaris Therapeutics, Inc. (ACRS) filed a Form 8-K on August 6, 2026 (Item 2.02) to announce its financial results for the quarter and six months ended June 30, 2026. The company furnished a press release dated August 6, 2026 as Exhibit 99.1, which contains the reported quarterly results and accompanying commentary. The Form 8-K was signed by CFO Kevin Balthaser.

Key Details

• Filing date: August 6, 2026 (Form 8-K, Item 2.02).
• Period covered: quarter and six months ended June 30, 2026.
• Press release furnished as Exhibit 99.1; cover page formatted in Inline XBRL filed as Exhibit 104.
• Report signed on the company’s behalf by Chief Financial Officer Kevin Balthaser.

Why It Matters
This 8-K signals that Aclaris has released its latest quarterly earnings and interim financial condition info—critical for investors tracking revenue, profitability, cash position, or guidance changes. The press release (Exhibit 99.1) will contain the detailed figures and management commentary; investors should review that release and any subsequent SEC filings (e.g., 10-Q) for the full financial data and implications for revenue, operating results, and near-term outlook.